Pharmaceutical composition comprising berberine and metformin and use thereof for treating or preventing atherosclerosis
Through the combination of berberine and metformin, the statin tolerance and side effects are solved, significantly reducing atherosclerosis plaques and related risk factors, and providing an effective alternative treatment for atherosclerosis.
Patent Information
- Application Number
- CN202110569787.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-08-18
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2041-08-18
AI Technical Summary
Existing statins have tolerance problems in the treatment of atherosclerosis, especially in Asian populations, and patients are concerned about potential side effects such as diabetes, cancer and memory loss, which leads to concerns about continued medication and the need to develop alternatives. drug.
Combining berberine and metformin as a drug combination, through molecular biology and high-fat feed-induced atherosclerosis animal model experiments, it was found that it can effectively reduce atherosclerosis plaques, body weight, TMA content and inflammatory response, forming a A new combination of drugs to treat or prevent atherosclerosis.
The combination of berberine and metformin significantly reduces atherosclerotic plaques induced by high-fat diet, which is better than the effect of individual administration of each component, effectively responds to statin intolerance patients and provides effective drugs for intolerance patients. Alternative treatment strategies and reduce multiple risk factors that cause atherosclerosis.
Smart Images

Figure BDA0003082196510000041 
Figure BDA0003082196510000051 
Figure BDA0003082196510000071
Abstract
Description
Technical Field
[0001] The invention relates to a pharmaceutical composition comprising berberine and metformin and use thereof in treating or preventing atherosclerotic diseases, belonging to the field of biopharmaceuticals. Background Art
[0002] According to statistics, cardiovascular and cerebrovascular diseases are the leading cause of death worldwide[1]. The mortality rate of cardiovascular diseases in my country has been ranked first for many years. The average age of patients has been gradually decreasing, and the prevalence is still in a stage of continuous increase. If the corresponding basic research and clinical treatment are not improved, it is estimated that by 2030, the risk of cardiovascular diseases in my country will increase by 50%. Therefore, the prevention and cure of cardiovascular diseases are becoming more and more important[2]. Atherosclerosis (AS) is the pathological basis of most cardiovascular diseases such as stroke, myocardial infarction and heart failure. It is the most common and most important type of atherosclerotic vascular disease. Its characteristics are that it starts with lesions in the intima of the artery, first with lipid and complex carbohydrate accumulation / bleeding and thrombosis, then with fibrosis and calcification, and with gradual degeneration and calcification of the middle layer of the artery. The lesions often involve elastic and large and medium muscular arteries. Once the arterial lumen is blocked, the tissues or organs supplied by the artery will be ischemic or necrotic. Because the lipids accumulated in the intima of the artery appear yellow porridge-like, it is called atherosclerosis.
[0003] AS is a chronic progressive vascular disease of large and medium arteries, mainly caused by lipid deposition in the inner wall of blood vessels. Its pathogenesis is relatively complex and is the result of the combined action of multiple risk factors. At present, there are four main theories surrounding the formation of atherosclerotic plaques characterized by lipid deposition in the blood vessel wall, namely, the inflammatory theory, the lipid infiltration theory, the oxidative theory, and the injury response theory. With the improvement of living conditions and changes in people's nutritional structure, blood sugar, dyslipidemia, and obesity caused by a long-term high-fat diet are common risk factors for the occurrence of AS. Moreover, these risk factors can be interrelated and have a certain causal relationship, jointly promoting the formation of AS [3].
[0004] In recent years, TMAO has been found to be closely related to atherosclerosis. Nutrients such as lecithin, carnitine, and choline contained in food are metabolized by intestinal flora to produce trimethylamine (TMA), which is then absorbed into the blood through the intestine and finally converted into TMAO by flavin monooxygenase (FMOs) in the liver. This substance is one of the high-risk factors for cardio-metabolic diseases such as atherosclerosis, thereby inducing or aggravating atherosclerosis in the body. Its pathogenic mechanisms mainly include upregulating scavenger receptors on the surface of macrophages, inhibiting the reverse transport of cholesterol, reducing key enzymes in bile acid synthesis, and activating multiple inflammation-related pathways [4,5].
[0005] Therefore, in view of the pathogenesis of AS, the treatment of AS can start from the following aspects: first, lowering blood lipids; second, reducing inflammatory response; third, inhibiting the proliferation of vascular endothelium; fourth, regulating intestinal flora to inhibit TMA production. A large amount of data has been shown that AS lesions in experimental animals and confirmed by angiography in humans can partially regress after controlling and treating risk factors for a period of time, especially after intensive lipid-lowering therapy and anti-inflammatory therapy. Therefore, it has become the first-line treatment for AS. In the treatment of AS, statins are the most widely used drugs. They can not only lower blood lipids, but also have good anti-inflammatory effects and good tolerance. They are the first-line drugs for the prevention and treatment of AS in clinical practice. However, some patients, especially Asians, still have statin intolerance. Therefore, the risk of statin intolerance needs to be carefully considered when using them; moreover, some patients often worry about the potential risks of statins in causing diabetes, cancer, and memory loss, and therefore have concerns about whether they need to continue taking the medicine. For patients with statin intolerance, it is urgent to develop effective drugs to replace statins.
[0006] Berberine
[0007] Berberine (BBR), also known as berberine, is the main alkaloid extracted from the traditional Chinese medicine Coptis chinensis. It has been used as an antibacterial and antidiarrheal drug in clinical practice. In recent years, with the deepening of research, its clinical use has been expanded to various aspects such as cardiovascular diseases, metabolic diseases, neurodegenerative diseases and tumors. Berberine has a very wide range of mechanisms of action and is a typical multi-target drug (such as LDLR, PCSK9, AMPK, InsR, PPARγ / α, PKC, GLUT1, LXRα / Fas). In addition, its extensive pharmacological effects are also related to regulating intestinal flora. After Zhu et al. gave BBR (0.5 g / L drinking water) to ApoE(- / -) mice fed a high-fat diet for 14 weeks, they observed that the better anti-atherosclerotic effect of BBR was related to regulating the structure of intestinal flora, increasing the abundance of Akkermansia in the intestine, and then reducing intestinal permeability [6].
[0008] Metformin
[0009] Metformin (MTF) is the most widely used drug for the treatment of type 2 diabetes worldwide. It is currently recognized that it promotes the phosphorylation of AMPK and activates multiple metabolism-related pathways downstream of AMPK, thereby promoting the consumption of sugar and fat and inhibiting glycogen and fat production. In addition to its good anti-diabetic effect, it also has certain anti-cancer, lipid-lowering, anti-inflammatory and anti-aging effects. It is hailed as a "magic drug" in the West, along with aspirin. Moreover, its wide range of clinical pharmacological effects are also related to regulating intestinal flora. Summary of the invention
[0010] The technical problem solved by the present invention is to provide a pharmaceutical composition comprising berberine compounds and biguanide compounds as active ingredients, and application of the pharmaceutical composition in preparing a drug for preventing or treating atherosclerotic diseases.
[0011] Based on molecular biology and high-fat diet-induced atherosclerosis animal model experiments, the inventors found that the combination of berberine and metformin can effectively reduce atherosclerotic plaques in ApoE(- / -) mice induced by a high-fat diet, and can effectively reduce multiple risk factors that lead to AS, such as body weight, TMA content, inflammatory response, and high fat, thereby forming the present invention.
[0012] In order to solve the technical problem of the present invention, the present invention provides the following technical solutions:
[0013] The first aspect of the technical solution of the present invention is to provide a pharmaceutical composition comprising berberine compounds and biguanide compounds as active ingredients.
[0014] The first aspect of the technical solution of the present invention also provides a pharmaceutical composition, which comprises a therapeutically effective amount of a berberine compound and a biguanide compound, and a pharmaceutically acceptable excipient.
[0015] In the above-mentioned pharmaceutical composition, the berberine compound is berberine or its derivatives, including berberine hydrochloride, berberine sulfate, berberine citrate, berberine phthalate or berberine alcohol.
[0016] In the above-mentioned pharmaceutical composition, the biguanide compound is metformin or its derivatives, including phenformin, phenformin hydrochloride, metformin, metformin hydrochloride, metformin sulfate, and buformin.
[0017] The pharmaceutical composition can provide a ratio of berberine dosage calculated as berberine hydrochloride to metformin dosage calculated as metformin hydrochloride of 1:4-1:0.25, preferably 1:2-1:0.5, more preferably 1:1.
[0018] The second aspect of the technical solution of the present invention provides use of the pharmaceutical composition described in the first aspect in preparing a drug for treating or preventing atherosclerosis.
[0019] The atherosclerotic disease is atherosclerosis or coronary heart disease, cerebral infarction, cerebral stroke, myocardial infarction, arrhythmia or peripheral vascular disease caused by atherosclerosis.
[0020] Beneficial technical effects
[0021] The present invention provides a new approach to prevent or treat atherosclerosis by administering berberine and metformin in combination. The combination of berberine and metformin of the present invention can significantly reduce atherosclerotic plaques in ApoE (- / -) mice induced by a high-fat diet, and can effectively reduce multiple risk factors for AS such as body weight, TMA content, inflammatory response, and high fat. Its effect is better than the effect of each component when it is administered alone, proving that there is a synergistic effect between the two components. The present invention can also effectively deal with atherosclerosis patients who are intolerant to statins, providing an effective drug replacement treatment strategy for these intolerant patients.
[0022] Specifically, the present invention establishes an AS model by feeding ApoE (- / -) mice with gene knockout with a high-fat diet (H10141, Beijing Huafukang Biotechnology Co., Ltd.). The animal is administered by oral administration of berberine / metformin mixed with a high-fat diet, and the modeling and administration are carried out simultaneously, and the administration is continued for 24 weeks. During the administration period, the weight of the animal is recorded every week; after the administration is completed, the eyeball is removed and blood is collected, and the animal is killed by dislocating the cervical vertebra, and the aortic blood vessels are retained. The aortic plaque condition is determined by gross oil red staining and HE staining experiments, the various cholesterol ester contents in plasma are determined by ultra-high resolution mass spectrometry, the levels of multiple inflammatory factors in plasma are determined by Luminex method, and the TMAO content in plasma is determined by LC-MS / MS method.
[0023] The experimental results show that berberine and metformin can effectively reduce atherosclerotic plaques in ApoE(- / -) mice induced by a high-fat diet, and can effectively reduce multiple important risk factors leading to AS, such as: reducing body weight, reducing the cholesterol ester content in the blood; reducing plasma TMAO levels, and reducing the levels of multiple inflammatory factors such as TNFα, IL-6, IL-1α, MCP-1 and IL-9 in the blood.
[0024] Therefore, berberine compounds and metformin compounds have a synergistic effect and are very effective drugs for preventing or treating atherosclerosis.
[0025] The present invention is described in detail below.
[0026] 1. Berberine compounds
[0027] In the present invention, the berberine compounds include berberine or its derivatives.
[0028] Berberine is berberine, which belongs to the isoquinoline alkaloids, with a molecular formula of C 20 H 18 NO 4 , molecular weight is 336.367; structural formula is:
[0029]
[0030] Berberine derivatives refer to compounds that can be metabolized into berberine in the body and exert their effects, including various acid salts of berberine and various derivatives obtained by modifying berberine. Acid salts include berberine hydrochloride, berberine sulfate, berberine citrate, berberine phthalate, etc. Berberine modified products include alcohol berberine, 13-n-octyl berberine, mangiferin berberine salt, 9-O-aryl substituted berberine, 13-hexyl berberine salt, etc.
[0031] In view of availability, the berberine compound of the present invention is preferably berberine, berberine hydrochloride or berberine sulfate, more preferably berberine hydrochloride.
[0032] 2. Biguanide compounds
[0033] In the present invention, biguanide compounds include metformin and its derivatives.
[0034] The molecular formula of metformin is C 4 H 11 N 5 , molecular weight is 129.167, structural formula is:
[0035]
[0036] Biguanide derivatives refer to compounds that can be metabolized into metformin in the body and exert their effects, including various derivatives obtained by modifying metformin, such as phenformin, phenformin hydrochloride, metformin, metformin sulfate, metformin hydrochloride, buformin, etc. Preferably, the biguanide compound is metformin or metformin hydrochloride.
[0037] 2. Atherosclerotic disease
[0038] In the present invention, atherosclerotic diseases include atherosclerosis or related disorders caused by atherosclerosis.
[0039] Atherosclerosis includes one or more of the following factors that may cause atherosclerosis: hyperlipidemia, obesity, hypertension, hyperglycemia, smoking, heredity, etc., especially atherosclerosis caused by hyperlipidemia.
[0040] According to the onset site, atherosclerosis includes coronary artery atherosclerosis, cerebral artery atherosclerosis, renal artery atherosclerosis, mesenteric artery atherosclerosis, lower limb artery atherosclerosis, etc. All of these are within the scope of the present invention.
[0041] Examples of related diseases caused by atherosclerosis include coronary heart disease, cerebral infarction, and peripheral vascular disease caused by atherosclerosis.
[0042] In some embodiments, the atherosclerosis-related diseases include related diseases caused by ischemia of tissues and organs due to atherosclerosis, including coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, and heart failure caused by coronary atherosclerosis; cerebral ischemia, cerebral thrombosis, cerebral atrophy, cerebral hemorrhage, and cerebral embolism caused by cerebral atherosclerosis; renal insufficiency, hypertension, glomerular fibrosis, renal failure, and uremia caused by renal atherosclerosis; abdominal pain after a full meal, indigestion, constipation, intestinal wall necrosis, and bloody stools caused by mesenteric atherosclerosis; intermittent claudication and gangrene caused by lower limb atherosclerosis.
[0043] 3. Pharmaceutical Composition
[0044] The dosage of the pharmaceutical composition of the present invention can vary widely according to the nature and severity of the disease to be prevented or treated, the individual conditions of the patient or animal, the route of administration and the dosage form. Generally speaking, for administration to human subjects, the dosage of berberine hydrochloride compound is 5-30 mg / kg / day, preferably 10-20 mg / kg / day, more preferably 10 mg / kg / day; the dosage of metformin hydrochloride compound is 5-30 mg / kg / day, preferably 10-20 mg / kg / day, more preferably 10 mg / kg / day. In a preferred embodiment, when administered in combination, the ratio (weight ratio) of the dosage of berberine compound to the dosage of metformin compound is 1:4-1:0.25, preferably 1:2-1:0.5, more preferably 1:1. It should be noted that, herein, the dosage of berberine compound is calculated as berberine hydrochloride, and the dosage of metformin compound is calculated as metformin hydrochloride.
[0045] The berberine compound and the metformin compound can be administered simultaneously, separately or sequentially. For example, the berberine compound and the metformin compound can be administered simultaneously, or the berberine compound can be administered first and then the metformin compound can be administered within 3 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 1 hour or 2 hours after the administration, or vice versa.
[0046] Furthermore, the above-mentioned dosage may be administered as one dosage unit or divided into several dosage units, depending on the clinical experience of the physician and the dosage regimen including the use of other therapeutic means.
[0047] When the compound of the present invention and other anti-atherosclerotic drugs are present together in the pharmaceutical composition of the present invention, the dosage should be adjusted according to the actual situation.
[0048] 4. Prevention or treatment methods
[0049] In one embodiment, the present invention relates to a method for preventing or treating atherosclerotic diseases, comprising administering a therapeutically effective amount of a berberine compound and a metformin compound to a test animal. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1 : Quantitative results of plaque area of gross oil red staining of aorta in each group of ApoE(- / -) mice.
[0051] Figure 2 : Body weight changes of ApoE(- / -) mice in each group during drug administration.
[0052] Figure 3 : Changes in the levels of various cholesterol esters in the plasma of each group of ApoE(- / -) mice.
[0053] Figure 4 :Changes in plasma inflammatory factors in each group of ApoE(- / -) mice.
[0054] Figure 5 : Changes of plasma TMA and TMAO levels in each group of ApoE(- / -) mice. DETAILED DESCRIPTION
[0055] 1. Experimental design:
[0056] Berberine was purchased from Nanjing Zelang Biotechnology Co., Ltd. (purity ≥ 98%), and metformin was purchased from Sangon Biotechnology (Shanghai) Co., Ltd. (purity ≥ 98%).
[0057] Clean-grade ApoE(- / -) mice (male, 6 weeks old, weighing 20-22 g) were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. The animals were housed in the Animal Center of the Institute of Materia Medica, Chinese Academy of Medical Sciences, with a constant temperature of 23±2°C and a humidity of 50-70%. Sterile bedding was changed twice a week, and food and water were available ad libitum.
[0058] The dosing and treatment of animals are as follows: After ApoE (- / -) mice adapted to the animal room for one week, they were divided into normal diet group (8 mice), high-fat diet group (8 mice), low-dose berberine group (LB group, 100 mg / kg / day), high-dose berberine group (HB group, 200 mg / kg / day), low-dose metformin group (LM group, 100 mg / kg / day), high-dose metformin group (HM group, 200 mg / kg / day), and low-dose berberine and metformin combination group (B+M group, 100 mg / kg / day berberine + 100 mg / kg / day metformin). The dosing method was oral administration by mixing the drug with high-fat diet feed. Modeling and dosing were carried out simultaneously, and the dosing was continued for 24 weeks.
[0059] During the administration period, the body weight and food intake of the animals were recorded weekly; then the eyeballs were removed to collect blood (EDTA anticoagulation), the animals were killed by cervical dislocation, and the aorta was obtained for subsequent molecular, biochemical and pathological analysis.
[0060] All data were processed and statistically analyzed using Graphpad Prism 6.0 software. The mean values of all samples were compared using One-way ANOVA analysis. P<0.05 indicated statistically significant differences. *P<0.05, **P<0.01, ***P<0.001.
[0061] 2. Experimental results and analysis:
[0062] I. Berberine combined with metformin can significantly reduce atherosclerotic plaques
[0063] The quantitative results of the gross oil red staining of the aorta of each group of ApoE(- / -) mice are shown in Figure 1 As shown in Table 1. The results showed that compared with the normal diet group, the area of atherosclerotic plaques in the high-fat diet group increased significantly (***p<0.001). Berberine or metformin reduced the area of aortic atherosclerotic plaques in a dose-dependent manner. The combination of low-dose berberine and metformin significantly reduced the area of aortic plaques (**p<0.01), and the intensity of the effect was significantly better than that of each single-use group.
[0064] Table 1 Effect of each drug group on reducing atherosclerotic plaques
[0065]
[0066] This study used Kim Jong-kyun's q value to evaluate whether berberine and metformin combined treatment has a synergistic effect on reducing atherosclerotic plaques [7]. Kim Jong-kyun's q value is a calculation value used to evaluate whether there is a synergistic therapeutic effect between two different drugs. The calculation formula is: q = E (a+b) / (E a +E b -E a ×E b ), where E a 、E b is the inhibition rate when the two drugs act alone, E (a+b) is the inhibition rate when two drugs are used in combination (i.e., combined drug inhibition rate). The numerator in the calculation formula represents the "measured combined effect", and the denominator represents the "expected combined effect". The different numerical ranges of Jin Zhengjun's q value represent three results:
[0067] q<0.85: the inhibitory effects of the two drugs are antagonistic;
[0068] 0.85≤q<1.15: The inhibitory effects of the two drugs are simple additive effects;
[0069] Q≥1.15: There is a synergistic effect between the inhibitory effects of the two drugs.
[0070] After calculation, the average q value of the berberine combined with metformin group was 1.27, indicating that berberine and metformin showed obvious synergistic effect in inhibiting atherosclerotic plaques when used in combination at low concentrations, and the two can be prepared into a pharmaceutical composition with synergistic effect in treating atherosclerosis.
[0071] II. Berberine combined with metformin significantly reduces body weight
[0072] The weight of mice was recorded every week during the experiment, and the weight changes were as follows: Figure 2 The weight of the animals in each group at the end of the administration is shown in Table 2. The results show that compared with the high-fat diet model group, metformin has almost no effect on body weight; berberine alone can reduce the body weight of mice to a certain extent, but the statistical difference is not significant; low-dose berberine combined with metformin can significantly reduce the body weight of mice from the 12th week, and the animals in all groups were in good condition throughout the experiment without obvious adverse reactions.
[0073] Table 2 Animal body weight at the end of drug administration
[0074]
[0075] III. Berberine combined with metformin effectively reduces plasma cholesterol ester levels
[0076] Atherosclerosis is an inflammatory disease caused by lipid deposition on the inner wall of blood vessels. The protruding plaques on the surface of the arterial wall contain a large amount of lipid substances. Therefore, reducing the lipid content in the body is an important indicator for alleviating and treating atherosclerosis. By measuring the plasma cholesterol ester content ( Figure 3 ), it can be seen that the metformin group and the high-dose berberine group can significantly reduce the levels of various plasma cholesterol esters (including total cholesterol esters, saturated cholesterol esters, monounsaturated cholesterol esters and polyunsaturated cholesterol esters). Compared with the low-dose group used alone, the low-dose berberine and metformin combination group has a stronger effect on lowering cholesterol esters, but due to the obvious effect of metformin on lowering cholesterol esters, the effect of the combination of the two is equivalent to that of the high-dose metformin group.
[0077] IV. Berberine combined with metformin effectively reduces systemic inflammatory response
[0078] Inflammatory response plays an important role in the occurrence and development of atherosclerosis. Chronic immune inflammation mediated by inflammatory factors is the main cause of the occurrence and development of AS, which is mainly manifested by the continuous elevated levels of multiple proinflammatory factors in the body. In addition, inflammation will aggravate lipid metabolism disorders and induce the oxidation of low-density lipoprotein into oxidized low-density lipoprotein (Ox-LDL), which is more likely to cause AS. Therefore, reducing the body's inflammatory response state is one of the very important strategies for the treatment of atherosclerosis.
[0079] The Luminex method was used to measure the levels of multiple inflammatory factors in plasma, including tumor necrosis factor α (TNF-α), monocyte chemoattractant protein 1 (MCP-1), interleukin 1α (IL-1α), interleukin 1β (IL-1β), interleukin 6 (IL-6), and interleukin 9 (IL-9). The results were as follows: Figure 4 As shown in the figure, a high-fat diet tends to increase the levels of inflammatory factors, but there is no statistical difference; after berberine is administered, the high dose can significantly reduce the levels of various inflammatory factors; after metformin is administered, both the high and low dose groups can effectively reduce the levels of various pro-inflammatory factors; compared with the single-use group, the combination of berberine and metformin has a more obvious synergistic effect on the reduction of the four inflammatory factors TNF-α, MCP-1, IL-1α and IL-9. The above results show that the combination of the two can effectively reduce the inflammatory response state in the body.
[0080] V. Berberine combined with metformin effectively reduces trimethylamine oxide (TMAO) levels
[0081] After the trimethylamine produced by intestinal flora enters the body, it can be oxidized into trimethylamine oxide (TMAO) by the action of liver FMO. This substance is an important factor affecting atherosclerosis. This part of the experiment further evaluated the effective therapeutic effect of berberine combined with metformin on atherosclerotic diseases by measuring the plasma trimethylamine oxide level. The results are shown in Table 3 and Figure 5 As shown in the results, a high-fat diet can significantly increase the level of TMAO in plasma. Administration of berberine or metformin can effectively reduce the increase in TMAO content caused by a high-fat diet, and the low-dose combination of the two has a more significant effect on TMAO, which is better than either single-dose group.
[0082] Table 3 TMAO levels in the blood of animals in each group
[0083]
[0084] Industrial Applicability
[0085] The present invention provides a new approach to prevent or treat atherosclerotic diseases by co-administering berberine and metformin. The combination of berberine and metformin of the present invention can significantly reduce the aortic plaque area, and can also significantly reduce multiple risk factors for atherosclerosis such as body weight, plasma cholesterol ester content, systemic inflammatory response and plasma TMAO, thereby effectively treating atherosclerotic diseases caused by a high-fat diet, and the effect is better than the effect of each component when it is administered alone. Both drugs are marketed drugs with high clinical safety, and combined use can greatly reduce the single dose and further reduce adverse drug reactions.
Claims
1. Use of a pharmaceutical composition in the preparation of a drug for preventing or treating atherosclerotic diseases, the pharmaceutical composition comprising berberine or a derivative thereof and metformin or a derivative thereof as active ingredients, the berberine derivative being selected from berberine hydrochloride, berberine sulfate, berberine citrate, and berberine phthalate, the metformin derivative being selected from metformin hydrochloride and metformin sulfate, and the pharmaceutical composition being able to provide a berberine dosage calculated as berberine hydrochloride to a metformin dosage calculated as metformin hydrochloride of a ratio of 1:1.
